NCT00057616 2019-11-08
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Celgene
Phase 3 Completed
Clinical Trials
6 trialsNCT00179608 2019-11-08
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
Celgene
Phase 1 Completed
NCT00109005 2017-01-02
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00412581 2016-04-29
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00055562 2005-06-24
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Celgene
Phase 2/3 Completed